JP2015525071A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525071A5
JP2015525071A5 JP2015516160A JP2015516160A JP2015525071A5 JP 2015525071 A5 JP2015525071 A5 JP 2015525071A5 JP 2015516160 A JP2015516160 A JP 2015516160A JP 2015516160 A JP2015516160 A JP 2015516160A JP 2015525071 A5 JP2015525071 A5 JP 2015525071A5
Authority
JP
Japan
Prior art keywords
human
human immunoglobulin
chain variable
heavy chain
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525071A (ja
Filing date
Publication date
Priority claimed from US13/488,628 external-priority patent/US20130045492A1/en
Application filed filed Critical
Priority claimed from PCT/US2013/044257 external-priority patent/WO2013184761A1/en
Publication of JP2015525071A publication Critical patent/JP2015525071A/ja
Publication of JP2015525071A5 publication Critical patent/JP2015525071A5/ja
Pending legal-status Critical Current

Links

JP2015516160A 2012-06-05 2013-06-05 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 Pending JP2015525071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/488,628 US20130045492A1 (en) 2010-02-08 2012-06-05 Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US13/488,628 2012-06-05
PCT/US2013/044257 WO2013184761A1 (en) 2012-06-05 2013-06-05 Methods for making fully human bispecific antibodies using a common light chain

Publications (2)

Publication Number Publication Date
JP2015525071A JP2015525071A (ja) 2015-09-03
JP2015525071A5 true JP2015525071A5 (enExample) 2016-07-21

Family

ID=48652344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516160A Pending JP2015525071A (ja) 2012-06-05 2013-06-05 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法

Country Status (12)

Country Link
EP (1) EP2854523A1 (enExample)
JP (1) JP2015525071A (enExample)
KR (1) KR20150023535A (enExample)
CN (1) CN104582476B (enExample)
AU (1) AU2013271737A1 (enExample)
CA (1) CA2874846A1 (enExample)
HK (1) HK1208994A1 (enExample)
IL (1) IL235781A0 (enExample)
MX (1) MX2014014891A (enExample)
RU (1) RU2014153674A (enExample)
SG (2) SG10201609535TA (enExample)
WO (1) WO2013184761A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
KR20150126863A (ko) * 2013-03-13 2015-11-13 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
ES2808853T3 (es) * 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
EP3294775B1 (en) 2015-05-12 2021-07-14 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US20190037816A1 (en) 2016-01-13 2019-02-07 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
CN113302207B (zh) * 2018-11-16 2025-05-13 维尔托索宾科公司 Cd38和icam1抗体及其用途
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN118496357A (zh) * 2023-02-15 2024-08-16 康源博创生物科技(北京)有限公司 一种多肽以及包含其作为轻链的抗体
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146572T3 (es) * 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU6819494A (en) * 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
PT1652920E (pt) * 2001-10-01 2010-11-08 Deutsches Krebsforsch Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma
WO2003061363A2 (en) * 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
CN101962408A (zh) * 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
EP3456191A1 (en) * 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
SG183149A1 (en) * 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
ES2872081T3 (es) * 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada

Similar Documents

Publication Publication Date Title
JP2023011882A5 (enExample)
RU2014153674A (ru) Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JP7538907B2 (ja) 共通の軽鎖のマウス
JP2019076108A5 (enExample)
JP2015502177A5 (enExample)
JP2014110814A5 (enExample)
JP2015509380A5 (enExample)
JP2018138047A5 (enExample)
RU2019121863A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
JP2016512034A5 (enExample)
JP2014524243A5 (enExample)
JP2015505477A5 (enExample)
WO2014160202A4 (en) Mice expressing a limited immunoglobulin light chain repertoire
CN104244709B (zh) 共同轻链小鼠
JP2019076109A5 (enExample)
JP2015510767A5 (enExample)
JP2019047806A5 (enExample)
JP2015519076A5 (enExample)
RU2014127339A (ru) Мыши с гуманизированной легкой цепью
JP2021137030A5 (enExample)
JP2013535213A5 (enExample)
JP2017509355A5 (enExample)
KR20140024909A (ko) 공통 경쇄를 가진 항체를 발현하는 비-사람 동물
JP2010529042A5 (enExample)
RU2018129169A (ru) Грызуны, имеющие сконструированный участок разнообразия тяжелой цепи